Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global Alzheimer’s drugs market was valued at US$ 7 billion in 2016 and is projected to record an impressive CAGR of 9.5% over the forecast period (2017-2025).
The global Alzheimer’s drugs market growth is poised gain significant momentum, owing to the increasing product innovations and development of novel drugs by the key manufacturers in this market. Augmented government funding for research on Alzheimer’s pathophysiology is expected to help develop a multitude of treatments for the Alzheimer’s disease, which would further bolster the growth of the global Alzheimer’s drugs market.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1373
Growing geriatric population, improved diagnostics and development of novel drugs are the integral factors projected to drive the growth of the global Alzheimer’s drugs market. According to the World Population Prospect report 2017, there is significant gains in life expectancy achieved globally in past decade, life expectancy at birth rose from approximately 67 to 71 years and all regions shared in the rise of life expectancy and in next several decades it would rise up to 78 years on average.
According to market experts, diagnostic prospects for the Alzheimer’s disease are undergoing massive development. AC Immune and Piramal healthcare are currently developing the Tau-PET imaging agent for better diagnosis of Alzheimer’s disease since 2014. Current medication available for treating Alzheimer’s disease lowers the symptoms rather than targeting pathophysiology of disease. The key market players are presently looking forward to developing novel drugs for the treatment of disease. The Alzheimer’s disease market represents huge commercial potential and a successfully developed product could generate billions of dollars in revenue. For instance, Merck and Company bought an exclusive worldwide license from Japan’s Teijin Pharma in 2016 to develop an investigational, preclinical anti-tau antibody, which has disease modifying potential.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1373
For instance, Genentech and AC immune are also developing anti-tau antibody, TauRx in 2017 announced phase three results of investigational drug LMTX first tau aggregation inhibitor in Alzheimer’s disease. Numerous regulatory agencies are working on providing accelerated approvals to such drug candidate, For instance, in January 2018 FDA proposed new guidelines aimed at lowering the clinical study goals of Alzheimer’s disease drugs for treating earlier-stage patients who have not yet showed functional disability or clinical abnormality, this is part of efforts to expand access to safe and effective treatment options for many serious conditions including Alzheimer’s disease through accelerated approval for such drugs.
Browse Press Release: https://bit.ly/300u1W7
- The presence of a highly potential market is attributed to the growing ageing population, with increased life expectancy, and rising awareness about Alzheimer’s in regions, including North America, Europe, and Asia Pacific.
- North America holds the largest share in the global Alzheimer’s drugs market, owing to the high prevalence of Alzheimer’s disease and easy access to disease diagnosis and treatment in this region.
- The well-known players operating in the global Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S, and Teva Pharmaceuticals Industries Ltd.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1373
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027